Skip to content

Efficacy of Liberal Versus Restricted IV Fluid Approach in the Management of Sickle Cell Vaso-Occlusive Crisis

Fluid Management in Sickle Cell Disease Vaso-occlusive Crisis: Restrictive Versus Liberal Strategies: A Randomized Controlled Trial (FLASC Trial)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07188766
Acronym
FLASC
Enrollment
394
Registered
2025-09-23
Start date
2025-10-05
Completion date
2028-10-01
Last updated
2026-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SCD, Vaso Occlussive Crisis

Keywords

sickle cell disease, sickle cell crisis, intravenous fluid, emergency department

Brief summary

Sickle cell disease (SCD) is a prevalent inherited blood disorder characterized by vaso-occlusive crises (VOCs), which lead to severe pain and complications. Despite hydration being a cornerstone of VOC management, the optimal fluid strategy remains uncertain. This study evaluates restrictive versus liberal fluid management strategies in patients with acute VOC. This multi-center, open-label, non-inferiority RCT will enroll patients with SCD presenting with acute VOC. Participants will be randomized to either a restrictive or liberal intravenous fluid management protocol. Primary outcome is pain score reduction. Secondary outcomes include time to pain resolution, ED length of stay, hospital admission rate, cumulative opioid dose, adverse events (incidence of fluid overload, pulmonary congestion), acute chest syndrome, incidence of acute kidney injury, revisit rates within 72 hours of ED discharge, need for intensive care or high-dependency unit admission, need for additional interventions, and 28 days overall mortality. Data will be analyzed using intention-to-treat principles. We hypothesize that a restrictive fluid strategy will achieve non-inferior pain control compared to a liberal strategy, while minimizing fluid-related complications. This study will provide evidence to inform clinical guidelines for fluid management in SCD patients experiencing VOCs.

Detailed description

This study is a prospective, non-inferiority, open-label, multicenter randomized-controlled trial (RCT) conducted in the emergency departments (EDs) of tertiary care hospitals in Saudi Arabia. The primary objective is to compare two fluid management strategies- restrictive (intervention) vs. liberal (control) in adult sickle cell disease (SCD) patients hospitalized for VOC. The study evaluates whether a restrictive fluid approach is non-inferior to a liberal strategy in terms of pain resolution, hospitalization duration, and other clinical outcomes. Patients will be randomized upon ED admission, and their assigned fluid regimen will be administered within the first hour. Clinical teams will monitor outcomes throughout hospitalization or up to 28 days post-enrollment. Study Population 1. Recruitment Screening: All patients admitted to the ED with VOC will be screened for eligibility. Consent Model: A priori informed written consent will be obtained from conscious, coherent patients or substitute decision-makers. 2. Inclusion Criteria Age \>18 years with confirmed SCD diagnosis. Presenting with VOC requiring hospitalization. Numeric Pain Rating Scale (NPRS) \>5 Willingness to participate and provide informed consent. 3. Exclusion Criteria Requiring specialized IVF management per the physician's discretion. Cardiac/Renal Conditions: Congestive heart failure (CHF) or symptomatic systolic heart failure. Patients with ESRD on chronic dialysis. Hemodynamic Instability: Shock (SBP \<100 mmHg or MAP \<65) with hypoperfusion signs. Other Exclusions: Known/suspected pregnancy. Prior enrollment in this trial within the last 30 days. Concurrent enrollment in another trial affecting fluid management. Inability to obtain IV access. Trial Intervention 1. Screening & Randomization Screening occurs upon ED admission; evaluations must precede randomization. A screening log will track eligible vs. randomized patients. 2. Informed Consent An a priori consent model is used due to the conscious-coherent state of most SCD patients in VOC. Efforts will be made to obtain consent immediately from the patient or surrogate. 3. Intervention Arms A. Intervention (Restrictive)Keep-vein-open (KVO) rate only (minimal fluids to maintain IV patency). No additional IV fluids administered. B. Control (Liberal) 20 mL/kg IV bolus (NS or LR over 1 hour) + maintenance fluids (1.5-2 mL/kg/day). Initiation: Both regimens starts within 1 hour of ED admission and continue until ED discharge. Hospitalized Patients: Pain scores (NPRS) recorded at 24, 48, and 72 hours. Total fluid intake documented at hospital discharge.

Interventions

Keep vein open rate

Sponsors

Imam Abdulrahman Bin Faisal University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This is a prospective, non-inferiority, open label multicenter randomized controlled trial. Patients on Intervention Group (Restricted approach group) will receive maintenance intravenous fluids at a keep-vein-open (KVO) rate and no extra intravenous fluids is administered. Control Group (Liberal Approach Group) Patients will receive an IV bolus of 20 mL/kg of normal saline or lactated Ringer's over 1 hour, followed by maintenance fluids at 1.5-2 ml/kg times the calculated daily maintenance requirements.

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Patients \>18 years old with a confirmed diagnosis of SCD. 2. Presenting with a VOC. 3. NPRS \>5 4. Willingness to participate and provide informed consent.

Exclusion criteria

1. Patient requiring specialized IVF management as per the treating physician discretion. 2. Patients with congestive heart failure, and /or acute or chronic symptomatic systolic heart failure 3. Patients with ESRD on chronic dialysis 4. Patients with signs of shock (low SBP \<100 or MAP \< 65) and signs of hypo perfusion 5. Known or suspected pregnancy 6. Previously enrolled in this trial within the last 30 days 7. Enrolled in another trial study that interfered with fluid management 8. Unable to obtain IV access.

Design outcomes

Primary

MeasureTime frameDescription
Change in Pain intensityBaseline (within 30 minutes post admission), 1 hour, then hourly until ED discharge or 24- 48- and 72-hours post-admission ( for admitted patients)Measured using the Numeric Pain Rating Scale (NPRS)

Secondary

MeasureTime frameDescription
Time to pain resolutionup to 4 hoursNPRS score of ≤5
ED length of stayat least 4 hourstime elapsed from ED admission to ED discharge or admit to the wards
Hospital admission ratewithin 24 hours of ED admissionProportion of participants requiring inpatient admission
Cumulative Opioid Doseup to 4 hoursTotal opioid consumption during acute VOC episode
Revisit Rateswithin 72 hours post ED dischargePercentage of patients who revisited the emergency department
Overall Mortalitywithin 28 days post-enrollmentnumber of patients who died
Adverse eventsup to 7 daystotal number of patients who encountered allergic reactions, respiratory distress, pulmonary edema, and acute chest syndrome, development of tachypnea, hypoxia, cough, crackles on auscultation, elevated BP, need for respiratory support, heart failure (worsening of tachycardia, hepatomegaly, peripheral edema, and allergic reactions (urticaria, angioedema, hypotension, wheezing)

Countries

Saudi Arabia

Contacts

CONTACTMohammed S Alshahrani, MD
msshahrani@iau.edu.sa+966556966663
CONTACTLaila Perlas Asonto, RN
lasonto@iau.edu.sa
PRINCIPAL_INVESTIGATORMohammed S Alshahrani, MD

King Fahd Hospital of the University- Imam Abdulrahman Bin Faisal University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026